Kristine Hole1, C Gjestad2, K M Heitmann3, T Haslemo2, E Molden2,3, S Bremer4. 1. Center for Psychopharmacology, Diakonhjemmet Hospital, PO Box 23, Vinderen, 0319, Oslo, Norway. kristine.hole@diakonsyk.no. 2. Center for Psychopharmacology, Diakonhjemmet Hospital, PO Box 23, Vinderen, 0319, Oslo, Norway. 3. Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Oslo, Norway. 4. Department of Medical Biochemistry, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Abstract
PURPOSE: Individual variability in the endogenous CYP3A metabolite 4β-hydroxycholesterol (4βOHC) is substantial, but to which extent this is determined by genetic and nongenetic factors remains unclear. The aim of the study was to evaluate the explanatory power of candidate genetic variants and key nongenetic factors on individual variability in 4βOHC levels in a large naturalistic patient population. METHODS: We measured 4βOHC concentration in serum samples from 655 patients and used multiple linear regression analysis to estimate the quantitative effects of CYP3A4*22, CYP3A5*3, and POR*28 variant alleles, comedication with CYP3A inducers, inhibitors and substrates, sex, and age on individual 4βOHC levels. RESULTS: 4βOHC concentration ranged >100-fold in the population, and the multiple linear regression model explained about one fourth of the variability (R 2 = 0.23). Only comedication with inducers or inhibitors, sex, and POR genotype were significantly associated with individual variability in 4βOHC level. The estimated quantitative effects on 4βOHC levels were greatest for inducer comedication (+>313%, P < 0.001), inhibitor comedication (-34%, P = 0.021), and female sex (+30%, P < 0.001), while only a modestly elevated 4βOHC level was observed in carriers vs. noncarriers of POR*28 (+11%, P = 0.023). CONCLUSIONS: These findings suggest that the CYP3A4*22, CYP3A5*3, and POR*28 variant alleles are of limited importance for overall individual variability in 4βOHC levels compared to nongenetic factors.
PURPOSE: Individual variability in the endogenous CYP3A metabolite 4β-hydroxycholesterol (4βOHC) is substantial, but to which extent this is determined by genetic and nongenetic factors remains unclear. The aim of the study was to evaluate the explanatory power of candidate genetic variants and key nongenetic factors on individual variability in 4βOHC levels in a large naturalistic patient population. METHODS: We measured 4βOHC concentration in serum samples from 655 patients and used multiple linear regression analysis to estimate the quantitative effects of CYP3A4*22, CYP3A5*3, and POR*28 variant alleles, comedication with CYP3A inducers, inhibitors and substrates, sex, and age on individual 4βOHC levels. RESULTS: 4βOHC concentration ranged >100-fold in the population, and the multiple linear regression model explained about one fourth of the variability (R 2 = 0.23). Only comedication with inducers or inhibitors, sex, and POR genotype were significantly associated with individual variability in 4βOHC level. The estimated quantitative effects on 4βOHC levels were greatest for inducer comedication (+>313%, P < 0.001), inhibitor comedication (-34%, P = 0.021), and female sex (+30%, P < 0.001), while only a modestly elevated 4βOHC level was observed in carriers vs. noncarriers of POR*28 (+11%, P = 0.023). CONCLUSIONS: These findings suggest that the CYP3A4*22, CYP3A5*3, and POR*28 variant alleles are of limited importance for overall individual variability in 4βOHC levels compared to nongenetic factors.
Entities:
Keywords:
4β-hydroxycholesterol; CYP3A4; CYP3A5; Inducer; Inhibitor; POR
Authors: Violette M G J Gijsen; Ron H N van Schaik; Offie P Soldin; Steven J Soldin; Irena Nulman; Gideon Koren; Saskia N de Wildt Journal: Ther Drug Monit Date: 2014-04 Impact factor: 3.681
Authors: Sarah J Woolsey; Melanie D Beaton; Yun-Hee Choi; George K Dresser; Steven E Gryn; Richard B Kim; Rommel G Tirona Journal: Basic Clin Pharmacol Toxicol Date: 2015-10-14 Impact factor: 4.080
Authors: Renzo Wolbold; Kathrin Klein; Oliver Burk; Andreas K Nüssler; Peter Neuhaus; Michel Eichelbaum; Matthias Schwab; Ulrich M Zanger Journal: Hepatology Date: 2003-10 Impact factor: 17.425
Authors: F Josephson; L Bertilsson; Y Böttiger; L Flamholc; M Gisslén; V Ormaasen; A Sönnerborg; U Diczfalusy Journal: Eur J Clin Pharmacol Date: 2008-05-06 Impact factor: 2.953
Authors: Andrew Yates; Wasiu Akanni; M Ridwan Amode; Daniel Barrell; Konstantinos Billis; Denise Carvalho-Silva; Carla Cummins; Peter Clapham; Stephen Fitzgerald; Laurent Gil; Carlos García Girón; Leo Gordon; Thibaut Hourlier; Sarah E Hunt; Sophie H Janacek; Nathan Johnson; Thomas Juettemann; Stephen Keenan; Ilias Lavidas; Fergal J Martin; Thomas Maurel; William McLaren; Daniel N Murphy; Rishi Nag; Michael Nuhn; Anne Parker; Mateus Patricio; Miguel Pignatelli; Matthew Rahtz; Harpreet Singh Riat; Daniel Sheppard; Kieron Taylor; Anja Thormann; Alessandro Vullo; Steven P Wilder; Amonida Zadissa; Ewan Birney; Jennifer Harrow; Matthieu Muffato; Emily Perry; Magali Ruffier; Giulietta Spudich; Stephen J Trevanion; Fiona Cunningham; Bronwen L Aken; Daniel R Zerbino; Paul Flicek Journal: Nucleic Acids Res Date: 2015-12-19 Impact factor: 16.971
Authors: Wan Sun; Richard A Lirio; Jennifer Schneider; Jiri Aubrecht; Harisha Kadali; Mike Baratta; Parul Gulati; Ajit Suri; Tiffany Lin; Raghavan Vasudevan; Maria Rosario Journal: Clin Pharmacol Drug Dev Date: 2020-12-16